SlideShare une entreprise Scribd logo
1  sur  27
Télécharger pour lire hors ligne
Inter-firm comparison of
Cipla andTorrent
Pharmaceuticals
Presentation by:
Varun Nigam
Varun Balakrishnan
Soumya Mukherjee
Saurabh Mhase
Indian
Pharmaceutical
Market
India is the 14th
largest Pharma
Market in the
world!
Valued
at
Rs. 600 bn
15-17%
Growth
Rate
Dominated by Brande
d
Generic
s
0
100
200
300
400
500
600
FY2007 FY2008 FY2009 FY2010 FY2011 FY2012 FY2013
Indian Pharma Market
INR in billion
Growth
Drivers
Growin
g
Populat
ion
Increase in
Drug
Income level
Increase
Growing
incidence of
Chronic Ailments
Improving
Medical
Infrastrutu
re
Increased
Government
spending on
Healthcare
Availability of
new forms of
Treatment
Swot Analysis: Cipla
S W
O T
Support to cancer
patients
P. falciparum malaria
‘No Touch Breast
Scan’
Foremost player in
anti-infective and anti-
asthmatic
formulations
Strong employee
force
Limited market
share
Negative Campaign
of AHF
Venture into
Alzheimer’s disease
medication
Can use Viramune
generic to achieve
higher growth
Increased investment
Constant price
rises in the
Indian
The Indian
Rupee
depreciated
Fluctuations in
Swot Analysis: Torrent
S W
O T
High market Share
High Growth Rate
Strong Innovation
Global Presence
Low Employee
Strength
High Debts
Aquisations
Product Expansion
Emerging Markets
Constant price
rise
The Indian
Rupee
depreciated
Fluctuations in
currency
Cipla overview
• Cipla Limited is a pharmaceutical company based in Mumbai
• Cipla makes drugs to treat cardiovascular disease, arthritis etc.
• Market capitalization is US$ 5.6 billion (2013)
• Cipla has 34 manufacturing units in 8 locations across India and
has presence in 170 countries
• It has over 2000 products in 65 therapeutic categories
History of Cipla
• 1935- Founded in by Dr. K. A. Hamied
• Vision:To make India self-sufficient in healthcare
• 1939- Encouraged by Mahatma Gandhi by visiting the company
• 1960- API manufacturing technology
• 1996-World’s first transparent dry powder inhaler
• 2001- HIV medicines
• 2005- Anti bird-Flu drug invented within 2-3months
• 2012- Reached 20000 employees level
Overview ofTorrent Pharma
• Torrent Pharmaceuticals Ltd. is the flagship company of theTorrent Group
• Initially was named asTrinity Laboratories Ltd
• Operates in more than 50 countries with over 1000 product
• It has 7 fully owned subsidiaries
History ofTorrent Pharma
• 1970 – Founded by Mr. U N Mehta
• 1992- President's award for highest pharmaceuticals exports of Rs. 1570
million
• 1994- Almost doubled its manufacturing capacity
• 2001- India's ninth best company among capital intensive companies in
terms of ROCE in a study by ETIG-BCG
Current Market Price
Rs. 423.5 Rs. 526.3
As of 23-01-2014
Some of the Products
Cipla Drugs Purpose Cost (in Rs.)
Escitalopram Anti-depressant 840
Isotroin AcneTreatment 108
Entavir Chronic Hep-B 1400
Triomune HIV/AIDS 662
Oseltamivir Swine Flu 5022
Asthalin Asthma 67
Levoflox chemotherapeutic antibiotic 46
Cefoprox anti-bacterial 91.22
Montair anti-allergic 120
Vanlid anti-bacterial 900
Tachyra Cardiac 48
Some of the Products
Torrent Pharma
Drugs
Purpose Cost (in Rs.)
Enselin Cardiac 85
Azukon Pregnancy,Lactation 43
Calcigard Hypertension 12.39
Domstal Acute Nausea,Vomiting 35
Symbal Diabetes 112
Dilzem Calcium Channel blockers 23.84
Hexidol schizophrenia 38
Diclomax Arthritis 15
Promotil Cardiovascular 30.25
Zaplon Insomnia 60.14
Macrotor Respiratory 72
Key financials of the Companies (Year-to-Year)
Cipla
Item Mar ‘13 Mar ‘ 12 Mar ‘11 Mar ‘10 Mar ‘09
Total Income (Rs. In crores) 8,722.30 7,114.56 6,561.49 5,915.49 5,208.33
Percentage change in income
from previous year
22.6% 8.42% 10.92% 13.6% -
Total expenses (Rs. In crores) 6,374.03 5,384.4 5,149.1 4,408.85 4,103.0
Net Profit (Rs. In crores) 1,507.11 1,123.96 960.39 1,081.49 776.81
Percentage change in Net
Profit
34.08% 17.03% -11.2% 39.22% -
Total Equity Dividend (Rs. In
crores)
160.58 160.58 224.81 160.58 155.46
Shares in issue (in Lacs) 8,029.21 8,029.21 8,029.21 8,029.21 7,772.91
Earnings Per Share (Rs.) 18.77 14 11.96 13.47 9.99
Book value (Rs.) 110.47 94.04 82.36 73.55 55.86
TotalAssets (Rs. In crores) 9,835.33 7,562.48 7,053.43 5,919.16 5,290.99
Key financials of the Companies (Year-to-Year)
Torrent Pharmaceuticals
Item Mar ‘13 Mar ‘ 12 Mar ‘11 Mar ‘10 Mar ‘09
Total Income (Rs. In crores) 2,970.84 2,162.69 1,873.17 1,429.14 1,196.22
Percentage change in income
from previous year
37.4% 15.5% 31.06% 19.5% -
Total expenses (Rs. In crores) 2,197.51 1,698.06 1,418.23 1,032.11 929.16
Net Profit (Rs. In crores) 546.42 311.25 290.86 207.37 186.73
Percentage change in Net
Profit
75.6% 7.01% 40.3% 11.05% -
Total Equity Dividend (Rs. In
crores)
194.61 71.92 67.69 50.77 33.84
Shares in issue (in Lacs) 846.11 846.11 846.11 846.11 846.11
Earnings Per Share (Rs.) 64.58 36.79 34.38 24.51 22.07
Book value (Rs.) 195.14 154.17 129.18 104.11 86.59
TotalAssets (Rs. In crores) 2,230.25 1,764.65 1,665.09 1,403.26 1,214.75
Key financials of the Companies (Q to Q)
Cipla
Item Sept ‘13 June ‘ 13 Mar ‘13 Dec ‘12 Sept ‘12
Net Profit for the period (Rs.
Crores)
376.03 474.9 267.56 338.78 500.01
Percentage change in Net
profit
-20.81% 77.5% -21.02% -32.24% -
Torrent Pharmaceuticals
Item Sept ‘13 June ‘ 13 Mar ‘13 Dec ‘12 Sept ‘12
Net Profit for the period (Rs.
Crores)
114 182 214 153 83.84
Percentage change in Net
profit -37.36% -14.95% 39.86% 82.5% -
Cash Flow Comparison
Item Cipla
Torrent
Pharmaceuticals
Net Cash FromOperating
Activities (Rs. In crores)
1,381.34 -68.69
Net Cash (used in)/from
investing Activities (Rs. In
crores)
-2,064.16 -89.48
Net Cash (used in)/from
Financing Activities (Rs. In
crores)
732.83 25.49
Net (decrease)/increase In Cash
and Cash Equivalents (Rs. In
crores)
50.01 -132.68
Financial Ratios Comparison
Ratios Cipla Torrent Pharma
InventoryTurnover Ratio 3.5 3.98
DebtorsTurnover Ratio 5.18 4.46
InvestmentsTurnover Ratio 3.5 3.98
Fixed AssetsTurnover Ratio 1.65 2.35
Total AssetsTurnover Ratio 0.83 1.25
AssetTurnover Ratio 0.94 1.38
Ratio Analysis-
FY2013
Face value
2 5
Comment: The Interest rates are lower than the Bond’s
Coupon Rate for Torrent- Bonds are sold at a premium.
The nominal value or rupee value of a
security stated by the issuer.
Ratio Analysis-
FY2013
Current Ratio
1.95 1.59
Comment: Cipla can better meet its liabilities which are
due over the next 12 months and save more money.
=Current Assets/ Current Liabilities
Ratio Analysis-
FY2013
Quick Ratio
1.68 1.24
Comment: The position of Cipla is better.
=Quick Assets/ Current Liabilities
Ratio Analysis-
FY2013
Debt Equity
Ratio
0.11 0.3
5
Comment: Torrent has a high debt load than Cipla
=Total Debt/ Shareholder Equity
Ratio Analysis-
FY2013
Net Profit
Margin
17.87
%
18.85
%
Comment: Torrent more efficient in converting Sales into
actual Profit
=PAT/ Revenue
Ratio Analysis-
FY2013
Return on Capital Employed
(ROCE)
20.79
%
33.14
%
Comment: The Rate at which Torrent borrows is good
=EBIT/ (Total Assets-Current Liabilities)
The Better One – In terms of growth rate
Year toYear
highest
39.22% 75.6%
Quarter to
Quarter highest
77.5% 82.5%
The Better One – In terms of ratios
More Liquidity Better Net
Profit Margin
Less Debt Better ROCE
Interfirm comparison of Cipla and Torrent Pharmaceuticals

Contenu connexe

Tendances (20)

Presentation dabur
Presentation daburPresentation dabur
Presentation dabur
 
Dr. Reddy's Laboratories
Dr. Reddy's LaboratoriesDr. Reddy's Laboratories
Dr. Reddy's Laboratories
 
The dabur
The daburThe dabur
The dabur
 
Dabur presentation
Dabur presentationDabur presentation
Dabur presentation
 
Study On Pharmaceuticals Companies
Study On Pharmaceuticals CompaniesStudy On Pharmaceuticals Companies
Study On Pharmaceuticals Companies
 
Dabur ppt
Dabur pptDabur ppt
Dabur ppt
 
Indian Pharma Industry
Indian Pharma IndustryIndian Pharma Industry
Indian Pharma Industry
 
HUL BCG MATRIX
HUL BCG MATRIXHUL BCG MATRIX
HUL BCG MATRIX
 
MARKETING STRATEGY OF DABUR
MARKETING STRATEGY OF DABURMARKETING STRATEGY OF DABUR
MARKETING STRATEGY OF DABUR
 
A project report on dabur
A project report on daburA project report on dabur
A project report on dabur
 
Itc marketing project
Itc marketing projectItc marketing project
Itc marketing project
 
Report on cipla
Report on ciplaReport on cipla
Report on cipla
 
Hindustan unilever limited ppt
Hindustan unilever limited pptHindustan unilever limited ppt
Hindustan unilever limited ppt
 
cipla and sun pharma
cipla and sun pharmacipla and sun pharma
cipla and sun pharma
 
Cipla ppt presentation By Ajit R. Kulkarni
Cipla ppt presentation By Ajit R. KulkarniCipla ppt presentation By Ajit R. Kulkarni
Cipla ppt presentation By Ajit R. Kulkarni
 
Patanjali Business Strategies
Patanjali Business Strategies Patanjali Business Strategies
Patanjali Business Strategies
 
Dabur
DaburDabur
Dabur
 
Hul ppt
Hul ppt Hul ppt
Hul ppt
 
DR REDDYS LABS PPT
DR REDDYS LABS PPTDR REDDYS LABS PPT
DR REDDYS LABS PPT
 
ITC vs HUL ltd.
ITC vs HUL ltd. ITC vs HUL ltd.
ITC vs HUL ltd.
 

En vedette

Cipla is a leading pharmaceutical company in india with a strong and profitab...
Cipla is a leading pharmaceutical company in india with a strong and profitab...Cipla is a leading pharmaceutical company in india with a strong and profitab...
Cipla is a leading pharmaceutical company in india with a strong and profitab...Mayank Gupt
 
Presentation on cipla project
Presentation on cipla projectPresentation on cipla project
Presentation on cipla projectPratyush Mishra
 
Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx
Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptxTorrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx
Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptxSushain Raizada
 
For the Love of Constraints
For the Love of ConstraintsFor the Love of Constraints
For the Love of ConstraintsCharla Kunkel
 
1st BME Global Pharma Supply Chain Congress 2016
1st BME Global Pharma Supply Chain Congress 20161st BME Global Pharma Supply Chain Congress 2016
1st BME Global Pharma Supply Chain Congress 2016Christoph Feldmann
 
Get Ready for Solvency II with Oracle's Hyperion Profitability and Cost Manag...
Get Ready for Solvency II with Oracle's Hyperion Profitability and Cost Manag...Get Ready for Solvency II with Oracle's Hyperion Profitability and Cost Manag...
Get Ready for Solvency II with Oracle's Hyperion Profitability and Cost Manag...Alithya
 
Fs disclosures interim & segment reporting
Fs disclosures   interim & segment reportingFs disclosures   interim & segment reporting
Fs disclosures interim & segment reportingPeculiar Labstery
 
Financial analysis of cipla ltd
Financial  analysis of cipla ltdFinancial  analysis of cipla ltd
Financial analysis of cipla ltdRohit Rashinkar
 
Cipla acquisition proposition
Cipla acquisition propositionCipla acquisition proposition
Cipla acquisition propositionPuja Khemka
 
Sustainability measurement
Sustainability measurementSustainability measurement
Sustainability measurementMorgan Rider
 

En vedette (20)

Cipla
CiplaCipla
Cipla
 
ppt
pptppt
ppt
 
Cipla is a leading pharmaceutical company in india with a strong and profitab...
Cipla is a leading pharmaceutical company in india with a strong and profitab...Cipla is a leading pharmaceutical company in india with a strong and profitab...
Cipla is a leading pharmaceutical company in india with a strong and profitab...
 
Presentation on cipla project
Presentation on cipla projectPresentation on cipla project
Presentation on cipla project
 
Uniform costing
Uniform costingUniform costing
Uniform costing
 
Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx
Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptxTorrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx
Torrent pharmaceuticals ltd. by sushain mahajan to tafheen si rpptx
 
Cipla- VC15 Branding
Cipla- VC15 BrandingCipla- VC15 Branding
Cipla- VC15 Branding
 
For the Love of Constraints
For the Love of ConstraintsFor the Love of Constraints
For the Love of Constraints
 
1st BME Global Pharma Supply Chain Congress 2016
1st BME Global Pharma Supply Chain Congress 20161st BME Global Pharma Supply Chain Congress 2016
1st BME Global Pharma Supply Chain Congress 2016
 
A
AA
A
 
Get Ready for Solvency II with Oracle's Hyperion Profitability and Cost Manag...
Get Ready for Solvency II with Oracle's Hyperion Profitability and Cost Manag...Get Ready for Solvency II with Oracle's Hyperion Profitability and Cost Manag...
Get Ready for Solvency II with Oracle's Hyperion Profitability and Cost Manag...
 
Cipla
Cipla Cipla
Cipla
 
Fs disclosures interim & segment reporting
Fs disclosures   interim & segment reportingFs disclosures   interim & segment reporting
Fs disclosures interim & segment reporting
 
Cipla – IPO
Cipla – IPOCipla – IPO
Cipla – IPO
 
OS FINAL
OS FINALOS FINAL
OS FINAL
 
Financial analysis of cipla ltd
Financial  analysis of cipla ltdFinancial  analysis of cipla ltd
Financial analysis of cipla ltd
 
Cipla acquisition proposition
Cipla acquisition propositionCipla acquisition proposition
Cipla acquisition proposition
 
Sustainability measurement
Sustainability measurementSustainability measurement
Sustainability measurement
 
Cipla Global Ltd.
Cipla Global Ltd.Cipla Global Ltd.
Cipla Global Ltd.
 
Uniliver
UniliverUniliver
Uniliver
 

Similaire à Interfirm comparison of Cipla and Torrent Pharmaceuticals

Interfirm comparison
Interfirm comparisonInterfirm comparison
Interfirm comparisonvarunbalack
 
TTK Healthcare Q4FY15: Net profit up 40.48% y/y to INR45.67m; Buy
TTK Healthcare Q4FY15: Net profit up 40.48% y/y to INR45.67m; BuyTTK Healthcare Q4FY15: Net profit up 40.48% y/y to INR45.67m; Buy
TTK Healthcare Q4FY15: Net profit up 40.48% y/y to INR45.67m; BuyIndiaNotes.com
 
Coral Laboratories Q4FY15: Surplus scenario likely to continue for next three...
Coral Laboratories Q4FY15: Surplus scenario likely to continue for next three...Coral Laboratories Q4FY15: Surplus scenario likely to continue for next three...
Coral Laboratories Q4FY15: Surplus scenario likely to continue for next three...IndiaNotes.com
 
Dr. Reddy’s Lab acquisition of Venus Remedies Ltd.
Dr. Reddy’s Lab acquisition of Venus Remedies Ltd.Dr. Reddy’s Lab acquisition of Venus Remedies Ltd.
Dr. Reddy’s Lab acquisition of Venus Remedies Ltd.Apratim Saha
 
Firstcall recommend this pharma scrip after Q4FY15 revenue rise 18.10% y/y
Firstcall recommend this pharma scrip after Q4FY15 revenue rise 18.10% y/yFirstcall recommend this pharma scrip after Q4FY15 revenue rise 18.10% y/y
Firstcall recommend this pharma scrip after Q4FY15 revenue rise 18.10% y/yIndiaNotes.com
 
Shilpa Medicare: Buy for medium to long term investment
Shilpa Medicare: Buy for medium to long term investmentShilpa Medicare: Buy for medium to long term investment
Shilpa Medicare: Buy for medium to long term investmentIndiaNotes.com
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...IndiaNotes.com
 
Strengthen your portfolio with this strong pharma scrip
Strengthen your portfolio with this strong pharma scripStrengthen your portfolio with this strong pharma scrip
Strengthen your portfolio with this strong pharma scripIndiaNotes.com
 
Hester Biosciences FY15: Net profit up 45% y/y; Buy
Hester Biosciences FY15: Net profit up 45% y/y; BuyHester Biosciences FY15: Net profit up 45% y/y; Buy
Hester Biosciences FY15: Net profit up 45% y/y; BuyIndiaNotes.com
 
Working capital management of Aurobindo Pharmaceutical ltd
Working capital management of Aurobindo Pharmaceutical ltdWorking capital management of Aurobindo Pharmaceutical ltd
Working capital management of Aurobindo Pharmaceutical ltdArpanKhanna3
 
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesHester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesIndiaNotes.com
 
EQUITY ANALYSIS & VALUATION Dr Reddy's ppt
EQUITY ANALYSIS & VALUATION Dr Reddy's ppt EQUITY ANALYSIS & VALUATION Dr Reddy's ppt
EQUITY ANALYSIS & VALUATION Dr Reddy's ppt Pruthiviraj chinthala
 
IPO Analysis - Alkem Laboratories Ltd.
IPO Analysis - Alkem Laboratories Ltd.IPO Analysis - Alkem Laboratories Ltd.
IPO Analysis - Alkem Laboratories Ltd.choice broking
 
Investor presentation april 2015
Investor presentation april 2015Investor presentation april 2015
Investor presentation april 2015Ashwini0301
 
Aarti Drugs Ltd - Sep'18 Katalyst Wealth Alpha Report
Aarti Drugs Ltd - Sep'18 Katalyst Wealth Alpha Report Aarti Drugs Ltd - Sep'18 Katalyst Wealth Alpha Report
Aarti Drugs Ltd - Sep'18 Katalyst Wealth Alpha Report Katalyst Wealth
 
Healthcare Services Sector Update April 2018
Healthcare Services Sector Update April 2018Healthcare Services Sector Update April 2018
Healthcare Services Sector Update April 2018Duff & Phelps
 
Indian pharmaceutical indutry 2015
Indian pharmaceutical indutry 2015Indian pharmaceutical indutry 2015
Indian pharmaceutical indutry 2015Arrjit Parashar
 

Similaire à Interfirm comparison of Cipla and Torrent Pharmaceuticals (20)

Interfirm comparison
Interfirm comparisonInterfirm comparison
Interfirm comparison
 
TTK Healthcare Q4FY15: Net profit up 40.48% y/y to INR45.67m; Buy
TTK Healthcare Q4FY15: Net profit up 40.48% y/y to INR45.67m; BuyTTK Healthcare Q4FY15: Net profit up 40.48% y/y to INR45.67m; Buy
TTK Healthcare Q4FY15: Net profit up 40.48% y/y to INR45.67m; Buy
 
ATS Company Reports: Alembic pharma ltd.
ATS Company Reports: Alembic pharma ltd.ATS Company Reports: Alembic pharma ltd.
ATS Company Reports: Alembic pharma ltd.
 
Coral Laboratories Q4FY15: Surplus scenario likely to continue for next three...
Coral Laboratories Q4FY15: Surplus scenario likely to continue for next three...Coral Laboratories Q4FY15: Surplus scenario likely to continue for next three...
Coral Laboratories Q4FY15: Surplus scenario likely to continue for next three...
 
Dr. Reddy’s Lab acquisition of Venus Remedies Ltd.
Dr. Reddy’s Lab acquisition of Venus Remedies Ltd.Dr. Reddy’s Lab acquisition of Venus Remedies Ltd.
Dr. Reddy’s Lab acquisition of Venus Remedies Ltd.
 
Firstcall recommend this pharma scrip after Q4FY15 revenue rise 18.10% y/y
Firstcall recommend this pharma scrip after Q4FY15 revenue rise 18.10% y/yFirstcall recommend this pharma scrip after Q4FY15 revenue rise 18.10% y/y
Firstcall recommend this pharma scrip after Q4FY15 revenue rise 18.10% y/y
 
Shilpa Medicare: Buy for medium to long term investment
Shilpa Medicare: Buy for medium to long term investmentShilpa Medicare: Buy for medium to long term investment
Shilpa Medicare: Buy for medium to long term investment
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
 
Strengthen your portfolio with this strong pharma scrip
Strengthen your portfolio with this strong pharma scripStrengthen your portfolio with this strong pharma scrip
Strengthen your portfolio with this strong pharma scrip
 
Hester Biosciences FY15: Net profit up 45% y/y; Buy
Hester Biosciences FY15: Net profit up 45% y/y; BuyHester Biosciences FY15: Net profit up 45% y/y; Buy
Hester Biosciences FY15: Net profit up 45% y/y; Buy
 
ATS Company Reports: Shilpa medicare
ATS Company Reports: Shilpa medicareATS Company Reports: Shilpa medicare
ATS Company Reports: Shilpa medicare
 
Working capital management of Aurobindo Pharmaceutical ltd
Working capital management of Aurobindo Pharmaceutical ltdWorking capital management of Aurobindo Pharmaceutical ltd
Working capital management of Aurobindo Pharmaceutical ltd
 
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesHester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
 
ATS Company Reports: Adi finechem ltd.
ATS Company Reports:  Adi finechem ltd.ATS Company Reports:  Adi finechem ltd.
ATS Company Reports: Adi finechem ltd.
 
EQUITY ANALYSIS & VALUATION Dr Reddy's ppt
EQUITY ANALYSIS & VALUATION Dr Reddy's ppt EQUITY ANALYSIS & VALUATION Dr Reddy's ppt
EQUITY ANALYSIS & VALUATION Dr Reddy's ppt
 
IPO Analysis - Alkem Laboratories Ltd.
IPO Analysis - Alkem Laboratories Ltd.IPO Analysis - Alkem Laboratories Ltd.
IPO Analysis - Alkem Laboratories Ltd.
 
Investor presentation april 2015
Investor presentation april 2015Investor presentation april 2015
Investor presentation april 2015
 
Aarti Drugs Ltd - Sep'18 Katalyst Wealth Alpha Report
Aarti Drugs Ltd - Sep'18 Katalyst Wealth Alpha Report Aarti Drugs Ltd - Sep'18 Katalyst Wealth Alpha Report
Aarti Drugs Ltd - Sep'18 Katalyst Wealth Alpha Report
 
Healthcare Services Sector Update April 2018
Healthcare Services Sector Update April 2018Healthcare Services Sector Update April 2018
Healthcare Services Sector Update April 2018
 
Indian pharmaceutical indutry 2015
Indian pharmaceutical indutry 2015Indian pharmaceutical indutry 2015
Indian pharmaceutical indutry 2015
 

Plus de Varun Nigam

Microsoft's evangelism and the Anti-trust case
Microsoft's evangelism and the Anti-trust caseMicrosoft's evangelism and the Anti-trust case
Microsoft's evangelism and the Anti-trust caseVarun Nigam
 
5 products that failed
5 products that failed5 products that failed
5 products that failedVarun Nigam
 
Marketing Research report on insurance policies and companies in India
Marketing Research report on insurance policies and companies in IndiaMarketing Research report on insurance policies and companies in India
Marketing Research report on insurance policies and companies in IndiaVarun Nigam
 
Infographic on Lowe's
Infographic on Lowe'sInfographic on Lowe's
Infographic on Lowe'sVarun Nigam
 
The art of selling by Zig Ziglar
The art of selling by Zig ZiglarThe art of selling by Zig Ziglar
The art of selling by Zig ZiglarVarun Nigam
 
Coke ahh campaign
Coke ahh campaignCoke ahh campaign
Coke ahh campaignVarun Nigam
 
Uncommon Service
Uncommon ServiceUncommon Service
Uncommon ServiceVarun Nigam
 
Floor depot Marketing Model
Floor depot Marketing ModelFloor depot Marketing Model
Floor depot Marketing ModelVarun Nigam
 

Plus de Varun Nigam (8)

Microsoft's evangelism and the Anti-trust case
Microsoft's evangelism and the Anti-trust caseMicrosoft's evangelism and the Anti-trust case
Microsoft's evangelism and the Anti-trust case
 
5 products that failed
5 products that failed5 products that failed
5 products that failed
 
Marketing Research report on insurance policies and companies in India
Marketing Research report on insurance policies and companies in IndiaMarketing Research report on insurance policies and companies in India
Marketing Research report on insurance policies and companies in India
 
Infographic on Lowe's
Infographic on Lowe'sInfographic on Lowe's
Infographic on Lowe's
 
The art of selling by Zig Ziglar
The art of selling by Zig ZiglarThe art of selling by Zig Ziglar
The art of selling by Zig Ziglar
 
Coke ahh campaign
Coke ahh campaignCoke ahh campaign
Coke ahh campaign
 
Uncommon Service
Uncommon ServiceUncommon Service
Uncommon Service
 
Floor depot Marketing Model
Floor depot Marketing ModelFloor depot Marketing Model
Floor depot Marketing Model
 

Dernier

UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGUNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGlokeshwarmaha
 
A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.mcshagufta46
 
Building Your Personal Brand on LinkedIn - Expert Planet- 2024
 Building Your Personal Brand on LinkedIn - Expert Planet-  2024 Building Your Personal Brand on LinkedIn - Expert Planet-  2024
Building Your Personal Brand on LinkedIn - Expert Planet- 2024Stephan Koning
 
Upgrade Your Banking Experience with Advanced Core Banking Applications
Upgrade Your Banking Experience with Advanced Core Banking ApplicationsUpgrade Your Banking Experience with Advanced Core Banking Applications
Upgrade Your Banking Experience with Advanced Core Banking ApplicationsIntellect Design Arena Ltd
 
Michael Vidyakin: Introduction to PMO (UA)
Michael Vidyakin: Introduction to PMO (UA)Michael Vidyakin: Introduction to PMO (UA)
Michael Vidyakin: Introduction to PMO (UA)Lviv Startup Club
 
MC Heights construction company in Jhang
MC Heights construction company in JhangMC Heights construction company in Jhang
MC Heights construction company in Jhangmcgroupjeya
 
Mihir Menda - Member of Supervisory Board at RMZ
Mihir Menda - Member of Supervisory Board at RMZMihir Menda - Member of Supervisory Board at RMZ
Mihir Menda - Member of Supervisory Board at RMZKanakChauhan5
 
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...TalentView
 
PDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdfPDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdfHajeJanKamps
 
Anyhr.io | Presentation HR&Recruiting agency
Anyhr.io | Presentation HR&Recruiting agencyAnyhr.io | Presentation HR&Recruiting agency
Anyhr.io | Presentation HR&Recruiting agencyHanna Klim
 
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John MeulemansBCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John MeulemansBBPMedia1
 
Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access
 
Ethical stalking by Mark Williams. UpliftLive 2024
Ethical stalking by Mark Williams. UpliftLive 2024Ethical stalking by Mark Williams. UpliftLive 2024
Ethical stalking by Mark Williams. UpliftLive 2024Winbusinessin
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access
 
PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfPDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfHajeJanKamps
 
Intellectual Property Licensing Examples
Intellectual Property Licensing ExamplesIntellectual Property Licensing Examples
Intellectual Property Licensing Examplesamberjiles31
 
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfAMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfJohnCarloValencia4
 
Tata Kelola Bisnis perushaan yang bergerak
Tata Kelola Bisnis perushaan yang bergerakTata Kelola Bisnis perushaan yang bergerak
Tata Kelola Bisnis perushaan yang bergerakEditores1
 
Developing Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, OursDeveloping Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, OursKaiNexus
 
Cracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptxCracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptxWorkforce Group
 

Dernier (20)

UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISINGUNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
UNLEASHING THE POWER OF PROGRAMMATIC ADVERTISING
 
A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.A flour, rice and Suji company in Jhang.
A flour, rice and Suji company in Jhang.
 
Building Your Personal Brand on LinkedIn - Expert Planet- 2024
 Building Your Personal Brand on LinkedIn - Expert Planet-  2024 Building Your Personal Brand on LinkedIn - Expert Planet-  2024
Building Your Personal Brand on LinkedIn - Expert Planet- 2024
 
Upgrade Your Banking Experience with Advanced Core Banking Applications
Upgrade Your Banking Experience with Advanced Core Banking ApplicationsUpgrade Your Banking Experience with Advanced Core Banking Applications
Upgrade Your Banking Experience with Advanced Core Banking Applications
 
Michael Vidyakin: Introduction to PMO (UA)
Michael Vidyakin: Introduction to PMO (UA)Michael Vidyakin: Introduction to PMO (UA)
Michael Vidyakin: Introduction to PMO (UA)
 
MC Heights construction company in Jhang
MC Heights construction company in JhangMC Heights construction company in Jhang
MC Heights construction company in Jhang
 
Mihir Menda - Member of Supervisory Board at RMZ
Mihir Menda - Member of Supervisory Board at RMZMihir Menda - Member of Supervisory Board at RMZ
Mihir Menda - Member of Supervisory Board at RMZ
 
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
 
PDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdfPDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdf
 
Anyhr.io | Presentation HR&Recruiting agency
Anyhr.io | Presentation HR&Recruiting agencyAnyhr.io | Presentation HR&Recruiting agency
Anyhr.io | Presentation HR&Recruiting agency
 
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John MeulemansBCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
BCE24 | Virtual Brand Ambassadors: Making Brands Personal - John Meulemans
 
Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024
 
Ethical stalking by Mark Williams. UpliftLive 2024
Ethical stalking by Mark Williams. UpliftLive 2024Ethical stalking by Mark Williams. UpliftLive 2024
Ethical stalking by Mark Williams. UpliftLive 2024
 
Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024Borderless Access - Global B2B Panel book-unlock 2024
Borderless Access - Global B2B Panel book-unlock 2024
 
PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdfPDT 89 - $1.4M - Seed - Plantee Innovations.pdf
PDT 89 - $1.4M - Seed - Plantee Innovations.pdf
 
Intellectual Property Licensing Examples
Intellectual Property Licensing ExamplesIntellectual Property Licensing Examples
Intellectual Property Licensing Examples
 
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdfAMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
AMAZON SELLER VIRTUAL ASSISTANT PRODUCT RESEARCH .pdf
 
Tata Kelola Bisnis perushaan yang bergerak
Tata Kelola Bisnis perushaan yang bergerakTata Kelola Bisnis perushaan yang bergerak
Tata Kelola Bisnis perushaan yang bergerak
 
Developing Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, OursDeveloping Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, Ours
 
Cracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptxCracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptx
 

Interfirm comparison of Cipla and Torrent Pharmaceuticals

  • 1. Inter-firm comparison of Cipla andTorrent Pharmaceuticals Presentation by: Varun Nigam Varun Balakrishnan Soumya Mukherjee Saurabh Mhase
  • 2. Indian Pharmaceutical Market India is the 14th largest Pharma Market in the world! Valued at Rs. 600 bn 15-17% Growth Rate Dominated by Brande d Generic s
  • 3. 0 100 200 300 400 500 600 FY2007 FY2008 FY2009 FY2010 FY2011 FY2012 FY2013 Indian Pharma Market INR in billion
  • 4. Growth Drivers Growin g Populat ion Increase in Drug Income level Increase Growing incidence of Chronic Ailments Improving Medical Infrastrutu re Increased Government spending on Healthcare Availability of new forms of Treatment
  • 5. Swot Analysis: Cipla S W O T Support to cancer patients P. falciparum malaria ‘No Touch Breast Scan’ Foremost player in anti-infective and anti- asthmatic formulations Strong employee force Limited market share Negative Campaign of AHF Venture into Alzheimer’s disease medication Can use Viramune generic to achieve higher growth Increased investment Constant price rises in the Indian The Indian Rupee depreciated Fluctuations in
  • 6. Swot Analysis: Torrent S W O T High market Share High Growth Rate Strong Innovation Global Presence Low Employee Strength High Debts Aquisations Product Expansion Emerging Markets Constant price rise The Indian Rupee depreciated Fluctuations in currency
  • 7. Cipla overview • Cipla Limited is a pharmaceutical company based in Mumbai • Cipla makes drugs to treat cardiovascular disease, arthritis etc. • Market capitalization is US$ 5.6 billion (2013) • Cipla has 34 manufacturing units in 8 locations across India and has presence in 170 countries • It has over 2000 products in 65 therapeutic categories
  • 8. History of Cipla • 1935- Founded in by Dr. K. A. Hamied • Vision:To make India self-sufficient in healthcare • 1939- Encouraged by Mahatma Gandhi by visiting the company • 1960- API manufacturing technology • 1996-World’s first transparent dry powder inhaler • 2001- HIV medicines • 2005- Anti bird-Flu drug invented within 2-3months • 2012- Reached 20000 employees level
  • 9. Overview ofTorrent Pharma • Torrent Pharmaceuticals Ltd. is the flagship company of theTorrent Group • Initially was named asTrinity Laboratories Ltd • Operates in more than 50 countries with over 1000 product • It has 7 fully owned subsidiaries
  • 10. History ofTorrent Pharma • 1970 – Founded by Mr. U N Mehta • 1992- President's award for highest pharmaceuticals exports of Rs. 1570 million • 1994- Almost doubled its manufacturing capacity • 2001- India's ninth best company among capital intensive companies in terms of ROCE in a study by ETIG-BCG
  • 11. Current Market Price Rs. 423.5 Rs. 526.3 As of 23-01-2014
  • 12. Some of the Products Cipla Drugs Purpose Cost (in Rs.) Escitalopram Anti-depressant 840 Isotroin AcneTreatment 108 Entavir Chronic Hep-B 1400 Triomune HIV/AIDS 662 Oseltamivir Swine Flu 5022 Asthalin Asthma 67 Levoflox chemotherapeutic antibiotic 46 Cefoprox anti-bacterial 91.22 Montair anti-allergic 120 Vanlid anti-bacterial 900 Tachyra Cardiac 48
  • 13. Some of the Products Torrent Pharma Drugs Purpose Cost (in Rs.) Enselin Cardiac 85 Azukon Pregnancy,Lactation 43 Calcigard Hypertension 12.39 Domstal Acute Nausea,Vomiting 35 Symbal Diabetes 112 Dilzem Calcium Channel blockers 23.84 Hexidol schizophrenia 38 Diclomax Arthritis 15 Promotil Cardiovascular 30.25 Zaplon Insomnia 60.14 Macrotor Respiratory 72
  • 14. Key financials of the Companies (Year-to-Year) Cipla Item Mar ‘13 Mar ‘ 12 Mar ‘11 Mar ‘10 Mar ‘09 Total Income (Rs. In crores) 8,722.30 7,114.56 6,561.49 5,915.49 5,208.33 Percentage change in income from previous year 22.6% 8.42% 10.92% 13.6% - Total expenses (Rs. In crores) 6,374.03 5,384.4 5,149.1 4,408.85 4,103.0 Net Profit (Rs. In crores) 1,507.11 1,123.96 960.39 1,081.49 776.81 Percentage change in Net Profit 34.08% 17.03% -11.2% 39.22% - Total Equity Dividend (Rs. In crores) 160.58 160.58 224.81 160.58 155.46 Shares in issue (in Lacs) 8,029.21 8,029.21 8,029.21 8,029.21 7,772.91 Earnings Per Share (Rs.) 18.77 14 11.96 13.47 9.99 Book value (Rs.) 110.47 94.04 82.36 73.55 55.86 TotalAssets (Rs. In crores) 9,835.33 7,562.48 7,053.43 5,919.16 5,290.99
  • 15. Key financials of the Companies (Year-to-Year) Torrent Pharmaceuticals Item Mar ‘13 Mar ‘ 12 Mar ‘11 Mar ‘10 Mar ‘09 Total Income (Rs. In crores) 2,970.84 2,162.69 1,873.17 1,429.14 1,196.22 Percentage change in income from previous year 37.4% 15.5% 31.06% 19.5% - Total expenses (Rs. In crores) 2,197.51 1,698.06 1,418.23 1,032.11 929.16 Net Profit (Rs. In crores) 546.42 311.25 290.86 207.37 186.73 Percentage change in Net Profit 75.6% 7.01% 40.3% 11.05% - Total Equity Dividend (Rs. In crores) 194.61 71.92 67.69 50.77 33.84 Shares in issue (in Lacs) 846.11 846.11 846.11 846.11 846.11 Earnings Per Share (Rs.) 64.58 36.79 34.38 24.51 22.07 Book value (Rs.) 195.14 154.17 129.18 104.11 86.59 TotalAssets (Rs. In crores) 2,230.25 1,764.65 1,665.09 1,403.26 1,214.75
  • 16. Key financials of the Companies (Q to Q) Cipla Item Sept ‘13 June ‘ 13 Mar ‘13 Dec ‘12 Sept ‘12 Net Profit for the period (Rs. Crores) 376.03 474.9 267.56 338.78 500.01 Percentage change in Net profit -20.81% 77.5% -21.02% -32.24% - Torrent Pharmaceuticals Item Sept ‘13 June ‘ 13 Mar ‘13 Dec ‘12 Sept ‘12 Net Profit for the period (Rs. Crores) 114 182 214 153 83.84 Percentage change in Net profit -37.36% -14.95% 39.86% 82.5% -
  • 17. Cash Flow Comparison Item Cipla Torrent Pharmaceuticals Net Cash FromOperating Activities (Rs. In crores) 1,381.34 -68.69 Net Cash (used in)/from investing Activities (Rs. In crores) -2,064.16 -89.48 Net Cash (used in)/from Financing Activities (Rs. In crores) 732.83 25.49 Net (decrease)/increase In Cash and Cash Equivalents (Rs. In crores) 50.01 -132.68
  • 18. Financial Ratios Comparison Ratios Cipla Torrent Pharma InventoryTurnover Ratio 3.5 3.98 DebtorsTurnover Ratio 5.18 4.46 InvestmentsTurnover Ratio 3.5 3.98 Fixed AssetsTurnover Ratio 1.65 2.35 Total AssetsTurnover Ratio 0.83 1.25 AssetTurnover Ratio 0.94 1.38
  • 19. Ratio Analysis- FY2013 Face value 2 5 Comment: The Interest rates are lower than the Bond’s Coupon Rate for Torrent- Bonds are sold at a premium. The nominal value or rupee value of a security stated by the issuer.
  • 20. Ratio Analysis- FY2013 Current Ratio 1.95 1.59 Comment: Cipla can better meet its liabilities which are due over the next 12 months and save more money. =Current Assets/ Current Liabilities
  • 21. Ratio Analysis- FY2013 Quick Ratio 1.68 1.24 Comment: The position of Cipla is better. =Quick Assets/ Current Liabilities
  • 22. Ratio Analysis- FY2013 Debt Equity Ratio 0.11 0.3 5 Comment: Torrent has a high debt load than Cipla =Total Debt/ Shareholder Equity
  • 23. Ratio Analysis- FY2013 Net Profit Margin 17.87 % 18.85 % Comment: Torrent more efficient in converting Sales into actual Profit =PAT/ Revenue
  • 24. Ratio Analysis- FY2013 Return on Capital Employed (ROCE) 20.79 % 33.14 % Comment: The Rate at which Torrent borrows is good =EBIT/ (Total Assets-Current Liabilities)
  • 25. The Better One – In terms of growth rate Year toYear highest 39.22% 75.6% Quarter to Quarter highest 77.5% 82.5%
  • 26. The Better One – In terms of ratios More Liquidity Better Net Profit Margin Less Debt Better ROCE

Notes de l'éditeur

  1. by issuing drugs at low cost, Imminent commencement of the Fixed-Dose combination for treatment of uncomplicated P. falciparum malaria to tackle the 200+ million cases of malaria globally
  2. by issuing drugs at low cost, Imminent commencement of the Fixed-Dose combination for treatment of uncomplicated P. falciparum malaria to tackle the 200+ million cases of malaria globally
  3. if interest rates are higher than the bond's coupon rate, then the bond is sold at a discount (below par).
  4. The current ratio indicates a company's ability to meet short-term debt obligations. The current ratio measures whether or not a firm has enough resources to pay its debts over the next 12 months. 3.18, 1.39
  5. The ratio tells creditors how much of the company's short term debt can be met by selling all the company's liquid assets at very short notice.
  6. A company's debt to equity ratio shows you what proportion of debt or equity a company is using to finance its assets. 
  7. It shows the amount of each sales dollar left over after all expenses have been paid.
  8. is a measure of the returns that a business is achieving from the capital employed. ROCE indicates the efficiency and profitability of a company's capital investments.